News

05/05/14
GREER Laboratories, Inc. launches ORALAIR, the first and only sublingual allergy immunotherapy tablet with a mix of five grass allergens for the treatment of grass pollen allergy

ORALAIR (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue...

[more]
01/04/14
GREER® Laboratories, Inc. Announces FDA Approval of ORALAIR®, the First Sublingual Allergy Immunotherapy Tablet, for the Treatment of Grass Pollen Allergy

ORALAIR® (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue...

[more]

 

STALLERGENES GREER, A GLOBAL ALLERGY PLAYER THAT PLACES PATIENTS AT THE HEART OF ITS STRATEGY

 

Drawing on its in-depth knowledge of allergic diseases, and its unique expertise in allergy immunotherapy (AIT), Stallergenes Greer thereby offers a comprehensive approach to improving the lives of allergy patients.  

 

Patient expectations are at the core of Stallergenes Greer innovation strategy.

World leader in sublingual immunotherapy, Stallergenes Greer provides efficient and patient-friendly allergy immunotherapy treatment options, such as shorter protocols to reduce the duration of treatment and the new convenient tablet form.